Ani pharmaceuticals, inc. ANIP.US Overview
ANIP AI Analysis & Strategy
Analysis Conclusion
The stock has been awarded the top rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.
ANIP Current Performance
-1.46%
Ani pharmaceuticals, inc.
-1.12%
Avg of Sector
-0.84%
S&P500
ANIP Key Information
ANIP Financial Forecast
Unit : USD
ANIP Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | 1.7 | 70% | 24.1% | 197.12M | 49.7% | 4.4% | -5.4% |
| 2024Q2 | 1.34 | 5.5% | 22.9% | 148.33M | 12.5% | -15.3% | -1.7% |
| 2024Q1 | 1.02 | -20.3% | 9.7% | 138.04M | 18.4% | 7% | 13.2% |
| 2023Q4 | 1.21 | 3.4% | 23.5% | 137.43M | 28.7% | 9.5% | 0.9% |
| 2023Q3 | 1 | 31.6% | 25% | 131.65M | 39.7% | 7.7% | 7.5% |
ANIP Profile
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.